GYRE vs CRESY Comparison

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).